Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma

(2018) Steven B. Maron et al.   Cancer Discovery

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

(2017) Robert S McNeill et al.   NEURO-ONCOLOGY

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

(2017) Jon S. Zawistowski et al.   Cancer Discovery

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

(2016) D. Oddo et al.   CANCER RESEARCH

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor

(2016) Jorge Garcia Fortanet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

(2016) Ying-Nan P. Chen et al.   NATURE

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma

(2016) Ryuma Tokunaga et al.   Oncotarget

Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation

(2015) Jon J. G. Winter et al.   JOURNAL OF MEDICINAL CHEMISTRY

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

(2015) J. C. Hunter et al.   MOLECULAR CANCER RESEARCH

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

(2015) Severa Bunda et al.   Nature Communications

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

(2015) L. G. Ahronian et al.   Cancer Discovery

Activation of RAS family members confers resistance to ROS1 targeting drugs

(2015) Marilisa Cargnelutti et al.   Oncotarget

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

(2015) Anirudh Prahallad et al.   Cell Reports

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

(2015) E. Jokinen et al.   Therapeutic Advances in Medical Oncology

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

(2014) Piro Lito et al.   CANCER CELL

Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH

(2014) Kakoli Das et al.   CANCER LETTERS

Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1

(2014) Chris R. Evelyn et al.   CHEMISTRY & BIOLOGY

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

(2014) Daniel V. T. Catenacci et al.   PLoS One

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies

(2013) J.S. Ross et al.   GYNECOLOGIC ONCOLOGY

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

(2013) Emanuele Valtorta et al.   INTERNATIONAL JOURNAL OF CANCER

Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue

(2013) Todd Hembrough et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity

(2013) Austin M Dulak et al.   NATURE GENETICS

In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture

(2013) Hiroyuki Miyoshi et al.   Nature Protocols

Ras inhibition via direct Ras binding—is there a path forward?

(2012) Weiru Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

(2012) E Birkeland et al.   BRITISH JOURNAL OF CANCER

Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

(2012) A. M. Dulak et al.   CANCER RESEARCH

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

(2012) Hao-Hsuan Jeng et al.   Nature Communications

Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence

(2011) D. V. T. Catenacci et al.   Cancer Discovery

Multiple Decisive Phosphorylation Sites for the Negative Feedback Regulation of SOS1 via ERK

(2010) Yuji Kamioka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway

(2007) Marie Dance et al.   CELLULAR SIGNALLING